Latest Therapeutic Novelties and Patents in Pulmonary Hypertension
Georgia F. Hardavella, Georgios S. Dionellis, Christina G. Kantza, Nikolaos G. Koulouris and Manos Alchanatis
Affiliation: 122 Garytou Str, Aghia Paraskevi, Athens, P.C 15343, Greece.
Keywords: Developments, patents, pulmonary arterial hypertension, therapeutic advances, therapeutic novelties, right heart catheterisation, PAH, phosphodiesterase-type 5, cGMP, sildenafil, PHIRST, right ventricular hypertrophy, eNOS, bosentan, sitaxsentan, ambrisentan, ambrisentan therapy, treprostinil, Rho kinase inhibitor, monocrotaline, azaindole-1, PASMCs, iloprost, XNT, right ventricular systolic, pressure, RVSP, Riociguat, epidermal growth factor, gefitinib, erlotinib, lapatinib, ACT-293987, selexipag, topiramate, tissue factor pathway inhibitor, tissue factor-mediated, downstream signaling pathway, calcitonin gene related peptide, CGRP, AMPK, AICAR, traditional chinese medicine, TCM
Recent advances in technology and novel pharmaceutical research findings have added new grounds in the fields of medical treatment and quality of life of patients diagnosed with pulmonary arterial hypertension (PAH). Collective assessment of new data is mandatory and useful for specialist medical doctors. This review aims to present the latest therapeutic developments of the last two years (2009-2010) in PAH. Moreover, recent patents (of the year 2010) regarding therapeutic novelties in PAH that expand treatment modalities, are hereby presented.
Rights & PermissionsPrintExport